Third‐generation EGFR‐TKIs such as osimertinib and lazertinib showed clinically relevant BBB penetration and excellent intracranial efficacy in brain metastasis in EGFR‐mutated NSCLC [18]. Here, EGFR is linked to non-small cell lung carcinoma.